Details of Disease

Disease Name

C. difficile infection

Disease Class

1A04: Clostridium difficile enterocolitis

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISY1BZY: C. difficile infection

ICD-11

ICD-11: 1A04

ICD-10

ICD-10: A00-B99

Disease Identifiers

MONDO ID

MONDO_0000705

UMLS CUI

C0238106

MedGen ID

65946

HPO ID

HP:0032168

SNOMED CT ID

423590009

General Information of Disease (ID: DISY1BZY)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bezlotoxumab	DMTZC5G	Approved	Monoclonal antibody	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RBX2660	DMAPZSL	Phase 3	NA	[2]
SMT-19969	DMA6D5V	Phase 3	NA	[3]
NVB-302	DM5P9OE	Phase 1	Peptide	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2	ClinicalTrials.gov (NCT03931941) Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) (CD3-OLS). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03595566) To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2). U.S. National Institutes of Health.
4	Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020 May;19(5):311-332.